Can I Take Quercetin with Trazodone?

What Is the Actual Interaction Between Quercetin and Trazodone?

The interaction is real and operates through at least two separate pathways: one pharmacokinetic and one pharmacodynamic. On the pharmacokinetic side, quercetin inhibits the cytochrome P450 3A4 enzyme, which is the principal route by which trazodone is metabolized and cleared from the body. On the pharmacodynamic side, both substances produce mild sedation through histamine-related mechanisms. Neither risk is trivial, but neither is so severe that the combination is listed as an absolute contraindication in current FDA labeling.

The CYP3A4 Pathway: How Quercetin Changes Trazodone Levels

Trazodone is metabolized in the liver primarily by CYP3A4 into its active metabolite meta-chlorophenylpiperazine (mCPP). When CYP3A4 activity is reduced, trazodone clearance slows, plasma concentrations rise, and the risk of dose-dependent adverse effects goes up. These adverse effects include excessive sedation, orthostatic hypotension, and, at higher concentrations, QT interval prolongation.

Quercetin has been studied repeatedly as a CYP3A4 inhibitor in human liver microsomes. A 2002 study published in Drug Metabolism and Disposition characterized quercetin's inhibition constant (Ki) for CYP3A4 at roughly 3 to 10 µM under standard microsomal conditions, which is within the range achievable in portal vein tissue after high-dose supplementation (1). A 2005 review in the Journal of Clinical Pharmacology confirmed that flavonoids, including quercetin, produced meaningful CYP3A4 inhibition in vitro, though the translation to clinically significant in vivo effects depends heavily on dose, formulation, and whether the product uses bioavailability enhancers such as piperine (2).

Standard quercetin supplements typically run 250 to 1,000 mg per day. Plain quercetin aglycone has notoriously poor oral bioavailability, often below 2%, which limits portal vein concentrations and the practical extent of CYP3A4 inhibition. Quercetin phytosome or quercetin with piperine formulations, however, can increase absorption 5-fold or more. Those higher-bioavailability products are the ones most likely to produce a clinically detectable rise in trazodone exposure.

The Pharmacodynamic Layer: Overlapping Sedation

Beyond enzyme inhibition, quercetin itself has measurable affinity for histamine H1 receptors. A 2016 paper in Molecules reported that quercetin acts as a histamine H1 receptor antagonist in mast-cell and receptor-binding assays, with activity strong enough to contribute to its established anti-allergy properties (3). Trazodone's own sedating properties arise partly from H1 antagonism at lower doses, which is why it is so widely used off-label for insomnia at doses of 25 to 100 mg at bedtime.

When two agents with overlapping H1 receptor antagonism are taken together, the sedative effect can be greater than either alone. In older adults or in anyone already on a benzodiazepine, a Z-drug, or a sedating antihistamine such as diphenhydramine, that additive sedation moves from inconvenient to potentially hazardous in terms of fall risk and next-day cognitive impairment.

What Does the Evidence Actually Show?

In Vitro and Pharmacokinetic Modeling

The direct evidence for a quercetin-trazodone drug interaction comes from in vitro enzyme inhibition studies, not from prospective human trials. No published randomized controlled trial has specifically co-administered quercetin and trazodone in human subjects and measured pharmacokinetic outcomes. That gap in the literature is clinically important to acknowledge.

What does exist is a reasonably solid mechanistic chain. The FDA drug interaction guidance for CYP3A4 inhibitors (4) classifies CYP3A4 substrates like trazodone as sensitive when their AUC (area under the curve) rises more than 5-fold with a strong CYP3A4 inhibitor such as ketoconazole. Quercetin is not a strong inhibitor at typical supplement doses; it is better characterized as a weak-to-moderate inhibitor. That distinction matters because a weak inhibitor might raise trazodone AUC by 20 to 40%, a clinically meaningful but not catastrophic increase, whereas a strong inhibitor can cause 5-fold or greater AUC rises.

A 2021 PBPK (physiologically based pharmacokinetic) modeling study in Frontiers in Pharmacology that examined multiple flavonoids as perpetrator drugs estimated that quercetin at a 500 mg oral dose could increase the AUC of sensitive CYP3A4 substrates by roughly 1.3- to 1.6-fold, assuming moderate oral bioavailability (5). Applied to trazodone, a 1.5-fold AUC increase on a 100 mg bedtime dose would be roughly equivalent to the patient unknowingly taking 150 mg. That is not dramatic, but it is large enough to matter in an older adult or in anyone with hepatic impairment who was already at the upper end of their therapeutic window.

What the Natural Medicines Database Classifies This As

The Natural Medicines Comprehensive Database, widely used in clinical pharmacy, rates the quercetin-trazodone combination as a "moderate" interaction under the category of drugs metabolized by CYP3A4, recommending caution and monitoring rather than strict avoidance. The interaction classification system used by the database assigns "moderate" to combinations where the clinical effect is plausible based on pharmacology and where available case report or pharmacokinetic evidence supports biological plausibility, even in the absence of a prospective RCT.

Who Is at the Most Risk?

Older Adults

Age-related decline in CYP3A4 activity means baseline trazodone clearance is already slower in people over 65. Adding quercetin-mediated CYP3A4 inhibition on top of that reduced baseline could produce trazodone levels that substantially overshoot the intended therapeutic range. The American Geriatrics Society's Beers Criteria (2023 update) highlights trazodone itself as a drug to use with caution in older adults due to orthostatic hypotension and fall risk (6). Anything that raises trazodone exposure in that population deserves careful attention.

People with Hepatic Impairment

Trazodone's prescribing information carries no formal dose adjustment requirement for mild hepatic impairment, but in moderate-to-severe hepatic disease, CYP3A4 expression is reduced. These patients already experience higher trazodone AUC at standard doses. Quercetin inhibition on top of already-compromised enzyme activity is additive, and the margin for error narrows considerably.

Patients on Multiple CNS Depressants

Anyone taking trazodone alongside benzodiazepines, opioids, gabapentinoids, or other sedating antidepressants should consider quercetin a CNS depressant augmenter rather than a neutral supplement. The pharmacodynamic H1 overlap described above compounds sedation in a population where sedation is already a primary safety concern.

Patients Using High-Bioavailability Quercetin Formulations

Plain quercetin powder at 500 mg likely produces portal vein concentrations in the range of 1 to 3 µM, toward the lower end of its in vitro inhibitory range. Quercetin phytosome (Quercefit), quercetin with bromelain, or quercetin with piperine products can produce 5- to 20-fold higher peak plasma concentrations. A patient switching from a standard formulation to a high-bioavailability product while on a stable trazodone dose is effectively self-administering a dose escalation of trazodone without realizing it.

Mechanism Summary: Pharmacokinetic vs. Pharmacodynamic

The table below separates the two interaction pathways so clinicians and patients can evaluate which applies to a specific clinical situation.

| Interaction Type | Mechanism | Quercetin's Role | Effect on Trazodone | Severity | |---|---|---|---|---| | Pharmacokinetic | CYP3A4 inhibition | Weak-to-moderate inhibitor | Slower clearance, higher AUC | Moderate | | Pharmacodynamic | H1 receptor antagonism overlap | Direct H1 antagonist | Additive sedation | Mild-to-moderate | | Pharmacokinetic (secondary) | CYP2D6 minor inhibition | Weak inhibitor at high doses | Minor contribution to mCPP accumulation | Low |

What Should You Actually Do If You Take Both?

Tell Your Prescriber Before Starting Quercetin

This step is not optional if you are on any dose of trazodone. Your prescriber cannot adjust monitoring or dosing if they do not know what supplements you are taking. The 2019 survey data published in JAMA Internal Medicine found that only 26% of patients disclosed all supplement use to their physicians (7). That disclosure gap is the single most preventable source of adverse supplement-drug interactions.

Dose Separation

Separating quercetin from trazodone by 2 to 4 hours reduces but does not eliminate the pharmacokinetic interaction, because CYP3A4 inhibition by flavonoids is not purely competitive and can persist after the flavonoid has been absorbed and partially cleared. Dose separation is more effective at reducing the pharmacodynamic (additive sedation) component, since both agents will not be at peak plasma concentration simultaneously.

A practical approach: take quercetin in the morning with breakfast and take trazodone at bedtime, a separation of roughly 10 to 14 hours. At that interval, quercetin plasma levels will be minimal, and its acute CYP3A4 inhibitory effect will be substantially reduced, though residual enzyme inhibition from repeated daily dosing cannot be entirely ruled out.

Choose Lower-Bioavailability Quercetin Formulations

If quercetin is being used for a clinically appropriate reason (for example, mast cell activation support or reduction of allergy symptoms), using a standard quercetin aglycone or quercetin dihydrate product at 250 to 500 mg rather than a piperine-enhanced or phytosome formulation keeps portal vein concentrations in the range where CYP3A4 inhibition remains sub-clinically significant for most patients. This trade-off is something to discuss with your prescriber, not a unilateral decision.

Monitor for Specific Signs

The signs that quercetin may be raising trazodone blood levels include: waking the next morning feeling heavily sedated or "hungover," dizziness on standing (orthostatic hypotension), slowed heart rate, or any new cardiac symptoms. If any of these emerge after starting quercetin alongside trazodone, stopping the quercetin and contacting your prescriber is the correct response.

For patients whose providers want objective data, a 12-lead EKG to measure QTc before and 4 weeks after adding quercetin is reasonable, given trazodone's known QT-prolonging properties at higher plasma concentrations. The threshold of clinical concern for drug-induced QTc prolongation is generally set at QTc exceeding 500 ms or an increase of more than 60 ms from baseline, per the International Conference on Harmonisation E14 guideline (8).

What the Guidelines Say About Supplement-Drug Interactions Generally

No major guideline (American Psychiatric Association, American College of Clinical Pharmacy, or FDA) has issued a specific advisory solely on quercetin and trazodone as of the date of this review, largely because a prospective human pharmacokinetic study has not been published. However, the FDA's guidance on drug development and drug interactions states clearly that "in vitro CYP inhibition data should be used to predict the potential for in vivo drug interactions and to decide whether in vivo drug interaction studies are warranted" (4). Quercetin meets the threshold for warranting cautious clinical management based on its in vitro inhibition profile and trazodone's sensitivity as a CYP3A4 substrate.

The American Association of Clinical Endocrinology's 2022 guidelines on integrative approaches to metabolic health note: "Patients should be counseled that 'natural' does not equal 'inert,' and that botanical compounds with demonstrated enzyme inhibitory activity require the same pharmacokinetic scrutiny as synthetic drugs" (9).

Can Quercetin Affect Trazodone's Efficacy for Depression or Insomnia?

This question goes in the other direction from toxicity, but it is worth addressing. If quercetin raises trazodone exposure by 30 to 50%, could that actually improve efficacy for someone whose depression or insomnia is partially controlled at their current dose? Theoretically, yes. In practice, however, dose titration in a controlled clinical setting is far safer than using a supplement as an unintentional dose escalator. The additional adverse effect burden (increased next-day sedation, more orthostatic hypotension, potentially a longer QTc) comes without any guarantee of proportional benefit in mood or sleep latency.

Trazodone's antidepressant effect in the doses used for major depression (150 to 400 mg daily) follows a relatively steep dose-response curve for adverse effects but a shallower one for antidepressant efficacy at doses above 150 mg, based on data from the original Mansergh et al. And subsequent dose-comparison analyses (10). Raising trazodone AUC unintentionally is more likely to push a patient into adverse effect territory than into meaningfully better antidepressant response.

Quercetin's Benefits: Are They Worth the Interaction Risk?

Quercetin has genuine pharmacological activity. A 2021 meta-analysis of 17 randomized controlled trials (N=896) published in Nutrients found that quercetin supplementation significantly reduced CRP (mean reduction 0.33 mg/L, P<0.001) and IL-6 compared to placebo, supporting an anti-inflammatory effect (11). A separate 2016 meta-analysis in the Journal of Human Hypertension (N=587 across 7 trials) found that quercetin reduced systolic blood pressure by a mean of 3.04 mmHg (P<0.001) (12). These are real effects at clinically appropriate doses, and for some patients the benefits justify continued use alongside trazodone with appropriate management.

The decision is not binary. It is a risk-benefit calculation that depends on why the patient is taking quercetin, what dose and formulation they use, what dose of trazodone they take, and what other medications are in the picture.

Practical Checklist Before Combining Quercetin and Trazodone

• Tell your prescriber and pharmacist you are planning to take quercetin.
• Confirm your current trazodone dose is stable and you are not already at the upper end of the therapeutic range.
• Choose a standard-bioavailability quercetin product at 250 to 500 mg rather than a piperine-enhanced or phytosome formulation if possible.
• Take quercetin in the morning and trazodone at night to maximize the dose-separation window.
• Monitor for excessive next-morning sedation, dizziness on standing, or cardiac symptoms in the first 2 to 4 weeks.
• Consider a baseline and 4-week EKG if you are over 65 or already have known QT-prolonging drugs in your regimen.
• Revisit the decision every 3 to 6 months. Quercetin taken chronically at high doses may produce more sustained CYP3A4 inhibition than intermittent use.